CHCWM – Cancer & Hematology Centers of West Michigan

NGM831 (NGM Biopharmaceuticals)

Description:  A Phase 1 / 2 Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Mechanism of Action:  anti-ILT3 monoclonal antibody (promotes immune activation in the tumor microenvironment)

Target Patient Population:   Most Solid Tumors

Study Design:  Drug is given IV every 3 weeks